DLQ-02 is under clinical development by Dermaliq Therapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DLQ-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DLQ-02 overview
DLQ-02 is under development for the treatment of plaque psoriasis and alopecia areata (AA). The drug candidate acts by targeting calcineurin. It is administered through topical route and is based on hyliQ technology.
See Also:
Dermaliq Therapeutics overview
Dermaliq Therapeutics (Dermaliq) is a private pharmaceutical company that develop a new generation of premium topical therapies and medical skin care products. The company is headquartered in United States.
For a complete picture of DLQ-02’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.